SCHEMBL23328004

SCHEMBL23328004

Cc1ccnc(N2CCOCC2)c1CN

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 2/20 0.49
NUDT1 P36639 1/20 0.41
CYP1A2 P05177 2/20 0.40
CYP2C9 P11712 1/20 0.40
STK4 Q13043 1/20 0.40
STK3 Q13188 1/20 0.40
KDM4E B2RXH2 4/20 0.40
LMNA P02545 2/20 0.40
PDE10A Q9Y233 1/20 0.40
GAA P10253 1/20 0.40
ALDH1A1 P00352 2/20 0.39
MEN1 O00255 1/20 0.39
USP2 O75604 1/20 0.39
ALOX15 P16050 1/20 0.39
TSHR P16473 1/20 0.39
CYP2C19 P33261 1/20 0.39
KMT2A Q03164 1/20 0.39
HSD17B10 Q99714 1/20 0.39
CLK4 Q9HAZ1 1/20 0.39
PIK3CA P42336 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23344650 0.82 LRRK2 (0.47) LRRK2NUDT1CYP1A2CYP2C9STK4
SCHEMBL21921211 0.76 LRRK2 (0.52) LRRK2CYP1A2CYP2C9STK4STK3
SCHEMBL12179269 0.76 LRRK2 (0.52) LRRK2CYP1A2CYP2C9STK4STK3
SCHEMBL28556258 0.74 LRRK2 (0.50) LRRK2CYP1A2CYP2C9STK4STK3
SCHEMBL26797380 0.73 LRRK2 (0.52) LRRK2NUDT1CYP1A2CYP2C9STK4
SCHEMBL23327900 0.73 KDM4E (0.63) LRRK2KDM4ELMNAGAAALDH1A1
Hydrochloric Acid SCHEMBL18795453 0.73 LRRK2 (0.39) LRRK2KDM4ELMNAGAAALDH1A1
SCHEMBL3436634 0.72 CYP1A2 (0.56) LRRK2CYP1A2CYP2C9STK4STK3
SCHEMBL3287525 0.72 CYP1A2 (0.52) CYP1A2CYP2C9KDM4ELMNAGAA
SCHEMBL31214591 0.70 KDM4E (0.40) LRRK2CYP1A2CYP2C9KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3820860-B1 PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 LIEBER INST INC (US) 2025-10-15 EP disclosed
US-11993581-B2 Pyridazine compounds for inhibiting Nav1.8 LIEBER INSTITUE, INC (US) 2024-05-28 US disclosed
EP-3820860-A1 PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 Lieber Institute, Inc. (US) 2021-05-19 EP disclosed
US-20210139456-A1 PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 LIEBER INSTITUTE, INC 2021-05-13 US disclosed
US-20210139456-A1 PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 LIEBER INSTITUTE, INC 2021-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210139456-A1 PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 SCN8A, SCN5A, SCN2A LRRK2 1681/4885NUDT1 2368/4885CYP1A2 3404/4885
US-11993581-B2 Pyridazine compounds for inhibiting Nav1.8 SCN8A, SCN5A, SCN2A LRRK2 1681/4885NUDT1 2368/4885CYP1A2 3404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.